Back to Browse Journals » Clinical Interventions in Aging » Volume 2 » Issue 1

Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women

Authors Esteban Jódar-Gimeno

Published Date May 2007 Volume 2007:2(1) Pages 163—174

DOI

Published 16 May 2007

Esteban Jódar-Gimeno

Endocrinology and Metabolism Service, University Hospital “12 de Octubre”, Madrid, Spain. Associate Professor of Medicine Universidad Complutense, Madrid, Spain

Objective: To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis.

Sources: A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory agencies.

Study and data selection: Studies were selected according to relevance and availability. Relevant information (design, objectives, patients’ characteristics, outcomes, adverse events, dosing, etc) was analyzed.

Results: Different studies have shown that, when administered intermittently as a subcutaneous injection in the abdomen, PTH increases bone mineral density (BMD) and prevents vertebral fractures. On completion of PTH therapy (up to 24 months), there is evidence that sequential treatment with alendronate is associated with a therapeutic benefit in terms of increase in BMD. Further trials are necessary to determine long-term safety and the role of PTH in combination with other treatments for osteoporosis and the effect of repeated cycles of PTH followed by an anti-catabolic agent. There are currently no completed comparative trials with other osteoporosis treatments.

Conclusions: Full length PTH, given intermittently as an abdominal subcutaneous injection, appears to be a safe and efficacious treatment option for high risk osteoporosis. More data are needed to determine its specific role in osteoporosis treatment.

Keywords: postmenopausal osteoporosis, anabolic therapy, PTH (1–84)

Download Article [PDF] 

Readers of this article also read:

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]

Vaishampayan UN

Core Evidence 2014, 9:69-70

Published Date: 16 May 2014

Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm [Corrigendum]

Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L

International Journal of Nanomedicine 2013, 8:2129-2130

Published Date: 13 June 2013

The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia

Shao IH, Hou CP, Chen SM, Chen CL, Lin YH, Chang PL, Tsui KH

Clinical Interventions in Aging 2013, 8:431-432

Published Date: 16 April 2013

Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica [Erratum]

Wang Z, Chen B, Quan G, Li F, Wu Q, Dian L, Dong Y, Li G, Wu C

International Journal of Nanomedicine 2013, 8:627-628

Published Date: 7 February 2013

Do calcifying nanoparticles really contain 16S rDNA?

Shiekh FA

International Journal of Nanomedicine 2012, 7:5051-5052

Published Date: 18 September 2012

Corrigendum

Chen ZQ, Liu Y, Zhao JH, Wang L, Feng NP

International Journal of Nanomedicine 2012, 7:1709-1710

Published Date: 30 March 2012